The Hepatitis B virus (HBV) is an important etiological factor for hepatocarcinogenesis, because HBV DNA load and HBV reactivation are major risks that influence the long-term survival of hepatocellular carcinoma (HCC) patients who underwent hepatectomy and, thus, may cause postoperative liver function deterioration, tumor recurrence, and reduce patient's overall survival. However, anti-HBV therapy can suppress HBV replication, improve the remnant liver function, render patients better able to tolerate HCC treatments, and may even improve their prognosis. In this paper, an anti-HBV therapy that benefits the prognosis of HBV-related HCC following hepatectomy is reviewed. © 2013 Society of Surgical Oncology.
CITATION STYLE
Yu, L. H., Li, N., Shi, J., Guo, W. X., Wu, M. C., & Cheng, S. Q. (2014, March). Does anti-HBV therapy benefit the prognosis of HBV- related hepatocellular carcinoma following hepatectomy? Annals of Surgical Oncology. https://doi.org/10.1245/s10434-013-3320-z
Mendeley helps you to discover research relevant for your work.